вторник, 31 мая 2011 г.

Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke

Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke.


Broader use of cholesterol-lowering statins may be a cost-effective fashion to restrain centre raid and stroke, US researchers suggest. In the study, published online Sept 27, 2010 in the register Circulation gudcef-200 medicine informationnavigation. The researchers also found that screening for exuberant receptiveness C-reactive protein (CRP) to pinpoint patients who may profit from statin psychotherapy is only cost-effective in set cases.



Elevated levels of CRP mark inflammation and suggest an increased gamble for heart attack and stroke indian brands rohypnol. Currently, statin analysis is recommended for high-risk patients - those with a 20 percent or greater endanger of some sort of cardiovascular event within the next 10 years.



But statins may also aid people with a lower risk, according to Dr Mark Hlatky, professor of vigorousness analysis and policy and of cardiovascular medicine at Stanford University School of Medicine in Stanford, Calif, and colleagues. Hlatky's gang set out to upon the cost-effectiveness of three statin remedy approaches in patients with sane cholesterol levels and no evidence of heart infection or diabetes: following current guidelines; conducting CRP screening in patients who don't answer in the air statin treatment guidelines and offering statins to those with animated CRP levels; and providing statin psychoanalysis based on a patient's cardiovascular chance alone, with no CRP testing.



The researchers analyzed which of the three approaches met the commonly accepted cost-effectiveness brink of no more than $50000 per quality-adjusted life-year. They found that statin cure based on cardiovascular hazard alone, without CRP testing, was the most cost-effective strategy.



Initiating statin healing at lower danger levels - without CRP testing - "would further put clinical outcomes at sufficient cost, making it the optimally cost-effective design in our analysis," the researchers wrote in a university hearsay release. "Ideally, a marker would tell us who will improve from drug treatment and who will not," Hlatky unmistakeable out in the release. "If a test could give us that information, it would be very cost-effective Diflucan. But there's not fitting evidence yet that CRP, or any other test, clockwork that well".

Комментариев нет:

Отправить комментарий